Zantac and Marrow hyperplasia - a phase IV clinical study of FDA data

Summary:

Marrow hyperplasia is reported as a side effect among people who take Zantac (ranitidine hydrochloride), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Furosemide, and have Idiopathic thrombocytopenic purpura.

The phase IV clinical study analyzes which people have Marrow hyperplasia when taking Zantac. It is created by eHealthMe based on reports of 432,014 people who have side effects when taking Zantac from the FDA, and is updated regularly.

What is Zantac?

Zantac has active ingredients of ranitidine hydrochloride. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 434,161 Zantac users. Check the latest studies of Zantac.

What is Marrow hyperplasia?

Marrow hyperplasia (increased bone marrow) is found to be associated with 279 drugs and 313 conditions by eHealthMe. Check the latest studies of Marrow hyperplasia.

On Jul, 26, 2026

432,014 people reported to have side effects when taking Zantac.
Among them, 12 people (0.0%) have Marrow hyperplasia.

Among these 12 people:

How long have people been on Zantac when they have Marrow hyperplasia? *

What is the gender of people who have Marrow hyperplasia when taking Zantac? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Marrow hyperplasia when taking Zantac? *

What are other drugs people take besides Zantac? *

What are other side effects people have besides Marrow hyperplasia? *

White Blood Cell Count Decreased: 3 people, 25.00%
Thrombocytopenia (decrease of platelets in blood): 3 people, 25.00%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 3 people, 25.00%
Acute Kidney Failure: 3 people, 25.00%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 25.00%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 3 people, 25.00%
Intestinal Ischaemia (decreased supply of oxygenated blood to the intestines): 2 people, 16.67%
Monocyte Percentage Increased: 2 people, 16.67%
Oedema Peripheral (superficial swelling): 2 people, 16.67%
Neutrophil Percentage Decreased: 2 people, 16.67%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 25.00%
Idiopathic Thrombocytopenic Purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting): 3 people, 25.00%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Zantac and have Marrow hyperplasia?

- Check whether Marrow hyperplasia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zantac:

Zantac (434,161 reports)

Browse all side effects of Zantac:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Marrow hyperplasia:

Marrow hyperplasia (279 drugs)

Browse all the conditions that are associated with Marrow hyperplasia:

Marrow hyperplasia (313 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranitidine hydrochloride (the active ingredients of Zantac) and Zantac (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.